Industry Outlook 2022

The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.

Surviving a long road, novel next-generation treatment offers hope for major depressive disorder.